Helicobacter Pylori Diagnostics Market Progresses for Huge Growth to 2026 EnvisaPosted by rushi007 on August 9th, 2019 Helicobacter pylori is a bacteria that resides on the lining of human stomach. Helicobacter produces chemicals, causing inflammation of stomach, which progresses to peptic ulcer or gastric cancer. Helicobacter pylori infection can be detected by simple and accurate tests such as breath test, blood tests, endoscopy, and stool tests. Based on the sample preparation, helicobacter pylori diagnostic assays are segmented into invasive methods, which includes immunoassay, rapid urease test, and histology, and Non-invasive methods, which includes stool antigen assay, serology test and urease breath test. Increasing infection prevalence in emerging economies and high demand for point-of-care testing are major factors driving growth of Helicobacter pylori diagnostics market. Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1874 Market Dynamics Market players are investing in developing point-of-care and accurate diagnostics products to gain competitive advantage. For instance, in 2017, Exaleza Bioscience launched Automated BreathID Hp Lab Urea Breath Testing System for detection of Helicobacter pylori. The system is point-of-care, with 99% sensitivity and specificity for H. pylori. Furthermore, companies are focusing enhancing product portfolio through inorganic growth strategies. For instance, Abbott Laboratories acquired Alere Inc., the global leader in point of care diagnostics, in order to expand its product portfolio and geographic presence. With this acquisition, Abbott could access to Alere’s rapid diagnostics segment, which includes H. pylori detection kits. However, limitations associated with the currently available diagnostic assays are expected to restrain the Helicobacter pylori diagnostics market. For instance, urea breath test and stool antigen test cannot be used in patients undergoing proton pump inhibitors treatment. Detailed Segmentation: Global Helicobacter Pylori Diagnostics Market, By Test Type: Invasive Immunoassay Rapid Urease Test Histology Non-invasive Stool Antigen Assays Serology Tests Urea Breath Test Global Helicobacter Pylori Diagnostics Market, By End User: Hospitals Clinics Diagnostic Laboratories Others Global Helicobacter Pylori Diagnostics Market, By Region: North America Europe Asia Pacific Latin America Middle East Africa Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1874 Increasing prevalence of helicobacter pylori in emerging economies is propelling the Helicobacter pylori diagnostics market growth Prevalence of helicobacter pylori is declining in developed countries, whereas its prevalence in emerging economies is increasing. For instance, according to the Faculty of Medicine of The Chinese University of Hong Kong (CUHK), 2017, around 4.4 billion people worldwide are infected with Helicobacter pylori (H. pylori). Furthermore, same source suggested that prevalence in Africa is up to 80%, which is the highest globally, while in Asia, over 50% of the population was infected with H. pylori. Moreover, according to the International Agency for Research on Cancer report 2014, in 2012, around 952,000 new gastric cancer cases occurred globally and around 734,000 gastric cancers were estimated to occur due to H. pylori infection. Such high prevalence of Helicobacter pylori in Africa and Asia is expected to fuel the regional helicobacter market growth. The limitations associated with diagnostic tests are expected to be a major factor restraining growth of the Helicobacter pylori diagnostics market. For instance, serology-based assays have low sensitivity and specificity, as they are unable to differentiate between active infection and IgG antibodies present in case of post treatment. Inorganic strategies by key players is fuelling growth of the Helicobacter pylori diagnostics market Key players involved in the global Helicobacter pylori diagnostics market include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., Diasorin S.P.A., Quidel Corporation, F. Hoffmann-La Roche Ltd.(Ventana Medical Systems, Inc.), Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Abbott Laboratories, Cardinal Health, Inc., and Halyard Health, Inc. Manufacturers are focusing on inorganic strategies, in order to enhance their product offerings. For instance, Diasorin S.P.A., in September 2017, acquired ELISA technology business from Siemens, with an aim of shifting the current client base that uses ELISA tests towards CLIA technology solutions. As a part of agreement, Siemens will continue to manufacture and supply ELISA immunodiagnostic kits exclusively for DiaSorin for the next three years. Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1874 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Like it? Share it! More by this author |